Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Endothelin receptor antagonists for pulmonary arterial hypertension: an overview Raja SGCardiovasc Ther 2010[Oct]; 28 (5): e65-71The last decade has seen major advances in the pharmacotherapy of pulmonary arterial hypertension (PAH). One of these advances has been the discovery of endothelin receptor antagonists (ERAs). ERAs are a class of potent vasodilators and antimitotic substances, which could specifically dilate and remodel pulmonary arterial system, and have been proposed as an alternative to traditional therapies for PAH. Current available evidence suggests that ERAs improve exercise capacity, functional status, pulmonary hemodynamics, and delay the time to clinical worsening for patients with PAH. This review attempts to provide an overview of the pharmacology, therapeutic benefits, and safety profile of ERAs in patients with PAH.|*Endothelin Receptor Antagonists[MESH]|Animals[MESH]|Antihypertensive Agents/adverse effects/pharmacokinetics/*therapeutic use[MESH]|Blood Pressure/drug effects[MESH]|Drug Interactions[MESH]|Endothelins/*metabolism[MESH]|Evidence-Based Medicine[MESH]|Familial Primary Pulmonary Hypertension[MESH]|Humans[MESH]|Hypertension, Pulmonary/drug therapy/metabolism/physiopathology[MESH]|Receptors, Endothelin/metabolism[MESH]|Treatment Outcome[MESH]|Vasodilator Agents/adverse effects/pharmacokinetics/*therapeutic use[MESH] |
